

Global Biotech Corp. Announces First Sale of the Purthanol Process License

Written by Australian Business

MONTREAL, Sept. 16, 2013 /PRNewswire/ - Global Biotech Corp. (OTCQB:GBIQ) (the "Company") is pleased to announce that it has just sold its first license to the rights to utilize the Purthanol process for the production of Athanol, a green-technology ethanol fuel alternative, for the Province of Quebec, Canada. Mr. Yvon Brin purchased the license on behalf of a newly formed corporation, Purthanol Quebec, that now owns this license. Further, the Company is currently in intensive talks to sell a second license and expects to conclude this sale within a short time-frame. A financial consideration for said sale has not been made public. We are also launching the new website of the company www.purthanol.com

About Global Biotech Corp

Global is a publicly traded company dedicated to investigating and developing natural products. It has recently changed its orientation to focus on green-technology fuel production with its acquisition of the Purthanol process for the ethanol product, Athanol. Visit www.purthanol.com for more information.

About Athanol

Athanol is an efficient and ecologically sound ethanol product. As of Q2 2013, Purthanol International, whose proprietary know-how, methodology and purchase orders for the Purthanol process was bought by Global Biotech in September 2013, began active work on its Athanol fuel production to fulfill purchase orders on hand.

CAUTIONARY STATEMENT

Other than statements of historical fact, included herein, all statements are forward-looking and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results may differ materially from Global's expectations and filings

Global Biotech Corp. Announces First Sale of the Purthanol Process License

Written by Australian Business

made with the securities regulators. The Company does not assume any obligation to update or revise its forward-looking statements. No stock exchange, securities commission or other regulatory authority has approved or disapproved this information.

SOURCE Global Biotech Corp